目的评估前列腺癌患者单纯雄激素去除治疗（androgen deprivation therapy，ADT）后的健康相关生活质量（health－related quality of life，HRQOL）。方法选取2014年6月至2015年6月接受单纯ADT且符合本研究入组标准的前列腺癌患者共20...目的评估前列腺癌患者单纯雄激素去除治疗（androgen deprivation therapy，ADT）后的健康相关生活质量（health－related quality of life，HRQOL）。方法选取2014年6月至2015年6月接受单纯ADT且符合本研究入组标准的前列腺癌患者共200例，平均年龄73.9岁。诊断前列腺癌时平均PSA为21.57 ng/ml。158例（79%）为局限性前列腺癌，因年龄、身体状况、基础疾病、患者个人意愿等接受ADT，42例（21%）为局部晚期或转移性前列腺癌，符合ADT指征。应用简明健康生活量表（the MOS item short from health survey，SF－36）、癌症患者生活质量测定量表的通用模块（functional assessment of cancer therapy－general module，FACT－G）、前列腺癌治疗功能评价量表（functional assessment of cancer therapy －prostate instrument，FACT－P）、抑郁自评量表（self－rating depression scale，SDS）和焦虑自评量表（self－rating anxiety scale，SAS）等调查患者的HRQOL。结果本组200例患者的SF－36生理健康总得分、心理健康总得分分别为（67.41±16.39）分、（64.81±17.51）分，表明患者总体生活质量尚可，除一般健康维度得分为（40.03±21.89）分，其余7个维度平均得分均〉60分。FACT－P中情感维度得分、前列腺癌模块得分以及FACT－P总分均较低，分别为（8.15±3.72）分、（12.30±4.04）分、（77.41±9.95）分，均不足最高得分的50%，而生理状况得分相对较好，为（20.41±4.29）分；且121例（61%）患者在FACT－P的＂我能够达到并保持勃起＂条目中选择了＂一点也不＂选项。SDS平均得分为（46.76±8.29）分，SAS平均得分为（43.25±9.69）分，分别有46例（23.0%）和43例（21.5）患者出现不同程度的抑郁和焦虑。结论前列腺癌患者接受单纯ADT后总体生活状况尚可，但出现了不同程度的抑郁、焦虑、勃起功能障碍等不良反应。展开更多
Background: Most newly diagnosed prostate cancers in Benin are metastatic diseases and patients are reluctant to undergo orchiectomy. Still, chemical androgen deprivation therapy is not always available and not every ...Background: Most newly diagnosed prostate cancers in Benin are metastatic diseases and patients are reluctant to undergo orchiectomy. Still, chemical androgen deprivation therapy is not always available and not every patient can afford it. Thus, it will be interesting to evaluate the results of that therapy in the country. Objective: To analyze the survival rate and factors influencing it in metastatic prostate cancer patients who underwent triptorelin-based androgen deprivation therapy at the former Military Teaching Hospital of Cotonou from January 1, 2012, to December 31, 2022. Patients and Method: Metastatic prostate cancer patients received intragluteal injections of triptorelin 11.25 mg every 3 months. We retrospectively collected follow-up data from the patients’ medical records. By means of the software StataTM version 15, we performed a descriptive analysis of qualitative data. We used Kaplan-Meir method to estimate the overall survival rate in the whole cohort and in specific subgroups of patients. We compared survival rates by using the log-rank test. Results: 68 metastatic prostate cancer patients aged 47-86 years (mean = 69.9) with initial PSA ranging from 24.25 to 6334 ng/mL (mean = 666.1) started triptorelin-based castration. The tumor grade in 21 (33.3%), 14 (22.2%), 15 (23.8), 8 (12.7%), and 5 (7.9%) patients was respectively ISUP grade groups 5, 4, 3, 2, and 1. 15 (22.1%), 4 (5.9%), 2 (2.9%), 1 (1.5%), 11 (16.2%), and 7 (10.3%) patients respectively had hypertension, diabetes mellitus, peptic ulcer, asthma, unilateral or bilateral hydronephrosis, and paralysis. The mean nadir PSA level was 22.5 ng/mL (range: 0.01-220.25). The mean time to nadir PSA level was 8.9 months (range: 3-57). The overall survival rate was 42.6%. There was no significant survival difference between age groups (p = 0.475), relating to the presence of diabetes or hypertension (p = 0.757) or to the presence of paralysis or hydronephrosis (p = 0.090). The initial PSA level exerted no significant impact on patients’ surviv展开更多
文摘目的评估前列腺癌患者单纯雄激素去除治疗（androgen deprivation therapy，ADT）后的健康相关生活质量（health－related quality of life，HRQOL）。方法选取2014年6月至2015年6月接受单纯ADT且符合本研究入组标准的前列腺癌患者共200例，平均年龄73.9岁。诊断前列腺癌时平均PSA为21.57 ng/ml。158例（79%）为局限性前列腺癌，因年龄、身体状况、基础疾病、患者个人意愿等接受ADT，42例（21%）为局部晚期或转移性前列腺癌，符合ADT指征。应用简明健康生活量表（the MOS item short from health survey，SF－36）、癌症患者生活质量测定量表的通用模块（functional assessment of cancer therapy－general module，FACT－G）、前列腺癌治疗功能评价量表（functional assessment of cancer therapy －prostate instrument，FACT－P）、抑郁自评量表（self－rating depression scale，SDS）和焦虑自评量表（self－rating anxiety scale，SAS）等调查患者的HRQOL。结果本组200例患者的SF－36生理健康总得分、心理健康总得分分别为（67.41±16.39）分、（64.81±17.51）分，表明患者总体生活质量尚可，除一般健康维度得分为（40.03±21.89）分，其余7个维度平均得分均〉60分。FACT－P中情感维度得分、前列腺癌模块得分以及FACT－P总分均较低，分别为（8.15±3.72）分、（12.30±4.04）分、（77.41±9.95）分，均不足最高得分的50%，而生理状况得分相对较好，为（20.41±4.29）分；且121例（61%）患者在FACT－P的＂我能够达到并保持勃起＂条目中选择了＂一点也不＂选项。SDS平均得分为（46.76±8.29）分，SAS平均得分为（43.25±9.69）分，分别有46例（23.0%）和43例（21.5）患者出现不同程度的抑郁和焦虑。结论前列腺癌患者接受单纯ADT后总体生活状况尚可，但出现了不同程度的抑郁、焦虑、勃起功能障碍等不良反应。
文摘目的:探讨前列腺癌(prostate cancer,PC)患者中性粒细胞/淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)、血小板/淋巴细胞比值(platelet-to-lymphocyte radio,PLR)与雄激素剥夺疗法后病情进展的关联。方法:纳入2017年5月—2020年5月收治于三亚中心医院(海南省第三人民医院)的170例PC患者作研究对象,所有患者接受雄激素剥夺疗法并随访1年。将随访期间进展成去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)者纳入进展组,其余纳入稳定组。比较两组一般资料、NLR、PLR、单核细胞/淋巴细胞比值(monocyte-to-lymphocyte ratio,MLR)等检查结果,应用多因素Logistic回归分析接受雄激素剥夺治疗的患者进展至CRPC的相关因素,绘制受试者工作特征(receiver operating characteristic,ROC)曲线评估NLR和PLR对患者1年内发生CRPC的预测效能。结果:随访结束时排除14例失访及2例其他原因死亡患者,剩余154例中44例纳入进展组,110例纳入稳定组;两组Gleason评分、T分期、N分期例数分布比较,差异均有统计学意义(P<0.05);进展组NLR和PLR高于稳定组(P<0.05),两组前列腺特异性抗原(prostate specific antigen,PSA)水平及其最低值(PSA nadir)例数分布比较差异有统计学意义(P<0.05);观察到低NLR组患者1年累积死亡率低于高NLR组(log-rankχ^(2)=5.094,P=0.024);低PLR组患者1年累积死亡率低于高PLR组(log-rankχ^(2)=9.931,P=0.002);Gleason评分≥8分(OR=3.998,P=0.034)、PLR(OR=1.156,P<0.001)、NLR(OR=13.844,P<0.001)、T4分期(OR=16.252,P=0.048)为进展至CRPC的独立危险因素;NLR和PLR预测PC患者1年内发生CRPC的曲线下面积(area under the curve,AUC)分别为0.845和0.865,两者AUC值比较差异无统计学意义(P>0.05)。结论:前列腺癌患者基线NLR和PLR值与CRPC发生相关,二者未来可能成为预测CRPC的有效手段。
文摘Background: Most newly diagnosed prostate cancers in Benin are metastatic diseases and patients are reluctant to undergo orchiectomy. Still, chemical androgen deprivation therapy is not always available and not every patient can afford it. Thus, it will be interesting to evaluate the results of that therapy in the country. Objective: To analyze the survival rate and factors influencing it in metastatic prostate cancer patients who underwent triptorelin-based androgen deprivation therapy at the former Military Teaching Hospital of Cotonou from January 1, 2012, to December 31, 2022. Patients and Method: Metastatic prostate cancer patients received intragluteal injections of triptorelin 11.25 mg every 3 months. We retrospectively collected follow-up data from the patients’ medical records. By means of the software StataTM version 15, we performed a descriptive analysis of qualitative data. We used Kaplan-Meir method to estimate the overall survival rate in the whole cohort and in specific subgroups of patients. We compared survival rates by using the log-rank test. Results: 68 metastatic prostate cancer patients aged 47-86 years (mean = 69.9) with initial PSA ranging from 24.25 to 6334 ng/mL (mean = 666.1) started triptorelin-based castration. The tumor grade in 21 (33.3%), 14 (22.2%), 15 (23.8), 8 (12.7%), and 5 (7.9%) patients was respectively ISUP grade groups 5, 4, 3, 2, and 1. 15 (22.1%), 4 (5.9%), 2 (2.9%), 1 (1.5%), 11 (16.2%), and 7 (10.3%) patients respectively had hypertension, diabetes mellitus, peptic ulcer, asthma, unilateral or bilateral hydronephrosis, and paralysis. The mean nadir PSA level was 22.5 ng/mL (range: 0.01-220.25). The mean time to nadir PSA level was 8.9 months (range: 3-57). The overall survival rate was 42.6%. There was no significant survival difference between age groups (p = 0.475), relating to the presence of diabetes or hypertension (p = 0.757) or to the presence of paralysis or hydronephrosis (p = 0.090). The initial PSA level exerted no significant impact on patients’ surviv
